Skip to main content
Premium Trial:

Request an Annual Quote

Sartorius and ProMetic to Supply, Develop Plasma Protein-Separation Technology

NEW YORK, April 3 (GenomeWeb News) - Sartorius and ProMetic BioTherapeutics, a subsidiary of ProMetic Life Sciences, will jointly supply and develop technology for separate proteins from blood plasma, the companies said today.


ProMetic, based in Montreal, Canada, has been licensing its plasma protein -purification technology to the blood industry. Under the agreement, Sartorius of Göttingen, Germany, will supply licensees of ProMetic's technology with filtration equipment and consumables as a "preferred supplier and technology provider," according to the companies.


In addition, the two partners will co-develop ligand-membrane composites for the isolation of proteins from blood plasma and other sources, based on ProMetic's Mimetic Ligand technology and Sartorius' membrane chromatography technology, Sartobind.


The companies did not disclose financial terms of the agreement.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.